Boston Scientific Appoints Joseph M. Fitzgerald as COO and Restructures Into Three Reportable Segments
On October 7, 2026, Boston Scientific Corporation (NYSE: BSX) announced the appointment of Joseph M. Fitzgerald as executive vice president and chief operating officer, effective January 1, 2027. The company also revealed a restructuring plan to divide its operations into three reportable segments: Interventional Therapies, Rhythm, and another unnamed segment. This reorganization is intended to streamline the business structure for improved operational efficiency and strategic focus across key therapeutic areas. Fitzgerald brings extensive leadership experience in healthcare and has previously held executive roles at other medical device companies. The restructuring reflects Boston Scientific's ongoing efforts to adapt its organizational framework to evolving market demands and competitive pressures.
Tickers: $BSX